Business Context and Reporting Period
This Form 6-K filing by Entera Bio Ltd. covers the month of June 2021, with the report signed on June 22, 2021. The filing discloses the execution of an At Market Issuance Sales Agreement dated May 7, 2021, with B. Riley Securities, Inc., authorizing the potential sale of up to 5,000,000 shares of common stock.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the terms of a capital raising mechanism.
Material Changes
The primary material event is the establishment of an "at the market" offering program. Under the agreement, the Company may sell shares through the Sales Agent based on instructions regarding price and size limits. The Company is not obligated to sell any shares, and the offering will terminate upon the sale of all authorized shares or earlier termination by either party.
Guidance, Outlook, and Risks
The filing outlines the financial terms of the Sales Agreement, including a commission rate of up to 3.0% of the gross sales price per share paid to the Sales Agent. The Company has also agreed to provide customary indemnification and reimburse specified expenses. No specific business outlook, guidance, or risk factors beyond the standard securities law disclaimers are detailed in this specific report.
Investor Verification Checklist
- Verify the total number of shares sold under the Sales Agreement since May 7, 2021, in subsequent filings.
- Confirm the actual commission costs incurred relative to the 3.0% cap.
- Review the Company's shelf registration statement (Form F-3, No. 333-239843) for the full prospectus details.
- Monitor future Form 6-K or 20-F filings for updates on the remaining capacity of the 5,000,000 share authorization.